No significant improvement of cardiovascular disease risk indicators by a lifestyle intervention in people with Familial Hypercholesterolemia compared to usual care: Results of a randomised controlled trial

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Broekhuizen, Karen ^a   Van Poppel, Mireille N M ^a   Koppes, Lando L ^b   Kindt, Iris ^c   Brug, Johannes ^a   Van Mechelen, Willem ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c Foundation for the Identification of Persons with Inherited Hypercholesterolemia (StOEH)   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH PROMOTION; HUMAN; LIFESTYLE; MALE; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL MODEL; TIME;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COUNSELING; FEMALE; HEALTH PROMOTION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIFE STYLE; LINEAR MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS; TIME FACTORS; TRIGLYCERIDES;

EID: 84863603893     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-181     Document Type: Article

References (46)

1. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson DL, et al. Harrisons principles of internal medicine McGraw-Hill Medical Publishing Division, New York 17 2008 22753542
2. Familial Hypercholesterolemia. Goldstein J, Hobbs H, Brown M, The Metabolic and Molecular Bases of Inherited Disease McGraw-Hill, New York, Scriver C, Beaudet A, Sly WVD, 2001 2863 2913
3. Scientific steering committee on behalf of the simon broome register group. Risk of fatal coronary heart disease in familial hypercholesterolaemia, BMJ 1991 303 893 896 1933004
4. Health status and the challenges for prevention in The Netherlands. Treurniet HF, Hoeymans N, Gijsen R, Poos MJ, van Oers JA, Thien WM, Public Health 2005 119 159 166 10.1016/j.puhe.2004.05.018 15661124 (Pubitemid 40123474)
5. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. Yuan G, Wang J, Hegele RA, CMAJ 2006 174 1124 1129 10.1503/cmaj.051313 16606962
6. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Lancet 2005 366 1267 1278 16214597
7. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Lancet 2008 371 117 125 10.1016/S0140-6736(08)60104-X 18191683
8. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. BMJ 2008 337 2423 10.1136/bmj.a2423 19001495
9. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. Am J Cardiol 2008 102 1K 34K 10.1016/j.amjcard.2008.10.002 19068318
10. Environmental modulation of atherosclerosis end points in familial hypercholesterolemia. Hegele RA, Atheroscler Suppl 2002 2 5 7 11976071 (Pubitemid 38229257)
11. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Austin MA, Hutter CM, Zimmern RL, Humphries SE, Am J Epidemiol 2004 160 421 429 10.1093/aje/kwh237 15321838 (Pubitemid 39166974)
12. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Kotseva K, Wood D, Backer GD, Bacquer DD, Pyr̃l̃ K, Keil U, et al. J Cardiovasc Risk 2009 16 121 137
13. Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. Kromhout D, Menotti A, Kesteloot H, Sans S, Circulation 2002 105 893 898 10.1161/hc0702.103728 11854133 (Pubitemid 34174933)
14. Efficacy of multifactorial lifestyle interventions in patients with established cardiovascular diseases and high risk groups. Blokstra A, van DI, Verschuren WM, Eur J Cardiovasc Nurs 2010
15. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Lancet 2004 364 937 952 10.1016/S0140-6736(04)17018-9 15364185 (Pubitemid 39208455)
16. Familial hypercholesterolemia-improving treatment and meeting guidelines. Hopkins PN, Int J Cardiol 2003 89 13 23 10.1016/S0167-5273(02)00420-5 12727001 (Pubitemid 36519173)
17. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Civeira F, Atherosclerosis 2004 173 55 68 10.1016/j.atherosclerosis.2003.11.010 15177124 (Pubitemid 38224196)
18. Management of hereditary dyslipidaemia; the paradigm of autosomal dominant hypercholesterolaemia. Fouchier SW, Rodenburg J, Defesche JC, Kastelein JJ, Eur J Hum Genet 2005 13 1247 1253 10.1038/sj.ejhg.5201496 16189547 (Pubitemid 43090526)
19. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Schulz KF, Altman DG, Moher D, J Clin Epidemiol 2010 63 834 840 10.1016/j.jclinepi.2010.02.005 20346629
20. Motives of Belgian adolescents for using sunscreen: the role of action plans. De VH, Mesters I, Riet JV, Willems K, Reubsaet A, Cancer Epidemiol Biomarkers Prev 2006 15 1360 1366 10.1158/1055-9965.EPI-05-0877 16835337 (Pubitemid 44125295)
21. Can multiple lifestyle behaviours be improved in people with Familial Hypercholesterolemia? Results of a randomised controlled trial. Broekhuizen K, van Poppel M, Koppes L, Kindt I, Brug J, van Mechelen W, Int J Behav Nutr Phys Act 2011
22. Motivational interviewing: a systematic review and meta-analysis. Rubak S, Sandbaek A, Lauritzen T, Christensen B, Br J Gen Pract 2005 55 305 312 15826439 (Pubitemid 40520908)
23. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
24. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, et al. J Intern Med 2004 256 482 490 10.1111/j.1365-2796.2004.01405.x 15554949 (Pubitemid 39577582)
25. Precision and accuracy of blood lipid analyses by a portable device (Cholestech-LDX). Issa JS, Strunz C, Giannini SD, Forti N, Diament J, Arq Bras Cardiol 1996 66 339 342 9035449
26. Performance of the CardioChek PA and Cholestech LDX point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids. Panz VR, Raal FJ, Paiker J, Immelman R, Miles H, Cardiovasc J S Afr 2005 16 112 117 15915279 (Pubitemid 41103512)
27. Validation of a point of care lipid analyser using a hospital based reference laboratory. Carey M, Markham C, Gaffney P, Boran C, Maher V, Ir J Med Sci 2006 175 30 35 10.1007/BF03167964 17312826 (Pubitemid 46218035)
28. Linnan L, Steckler A, Process Evaluation for Public Health Interventions and Research Jossey-Bass, San Francisco, Linnan L, Steckler A, 2002 1 24
29. Moyers TB, Martin T, Manual JK, Miller WR, Ernst D, Revised Global Scales: Motivational Interviewing Treatment Integrity 3.0 (MITI 3.0) Center on Alcoholism, Substance Abuse and Addictions (CASAA), University of New Mexico 28 2007 Ref Type: Unpublished Work
30. Is verbatim transcription of interview data always necessary? Halcomb EJ, Davidson PM, Appl Nurs Res 2006 19 38 42 10.1016/j.apnr.2005.06.001 16455440 (Pubitemid 43181607)
31. Rubin DB, Multiple Imputation for Nonresponse in Surveys J Wiley & Sons, New York 1987
32. NHG-Standpunt Diagnostiek en behandeling van familiaire hypercholesterolemie. Walma E, Wiersma Tj, Huisarts Wet 2006 49 202 204
33. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. Huijgen R, Kindt I, Verhoeven SB, Sijbrands EJ, Vissers MN, Kastelein JJ, et al. PLoS One 2010 5 9220 10.1371/journal.pone.0009220 20169164
34. Global risk of coronary heart disease: assessment and application. Viera AJ, Sheridan SL, Am Fam Physician 2010 82 265 274 20672791
35. Biomarker evaluation does not confirm efficacy of computer-tailored nutrition education. Kroeze W, Dagnelie PC, Heymans MW, Oenema A, Brug J, J Nutr Educ Behav 2011 43 323 330 21906546
36. Short and long term effects of a lifestyle intervention for construction workers at risk for cardiovascular disease: a randomized controlled trial. Groeneveld IF, Proper KI, van der Beek AJ, Hildebrandt VH, van MW, BMC Publ Health 2011 11 836 10.1186/1471-2458-11-836
37. Dietary treatment for familial hypercholesterolaemia. Shafiq N, Singh M, Kaur S, Khosla P, Malhotra S, Cochrane Database Syst Rev 2010 D001918
38. The effects of motivational interviewing on physiological outcomes. Kreman R, Yates BC, Agrawal S, Fiandt K, Briner W, Shurmur S, Appl Nurs Res 2006 19 167 170 10.1016/j.apnr.2005.10.004 16877197 (Pubitemid 44131651)
39. Physical activity and dietary behavior change in Internet-based weight loss interventions: Comparing two multiple-behavior change indices. Carlson JA, Sallis JF, Ramirez ER, Patrick K, Norman GJ, Prev Med 2012 54 50 54 10.1016/j.ypmed.2011.10.018 22085706
40. Applying health behavior theory to multiple behavior change: considerations and approaches. Noar SM, Chabot M, Zimmerman RS, Prev Med 2008 46 275 280 10.1016/j.ypmed.2007.08.001 17825898 (Pubitemid 351305298)
41. Multiple health behavior change research: an introduction and overview. Prochaska JJ, Spring B, Nigg CR, Prev Med 2008 46 181 188 10.1016/j.ypmed.2008. 02.001 18319098 (Pubitemid 351305303)
42. Motivational interviewing in health settings: a review. Britt E, Hudson SM, Blampied NM, Patient Educ Couns 2004 53 147 155 10.1016/S0738-3991(03)00141- 1 15140454 (Pubitemid 38622059)
43. Motivational interviewing: an evidence-based approach to counseling helps patients follow treatment recommendations. Levensky ER, Forcehimes A, ODonohue WT, Beitz K, Am J Nurs 2007 107 50 58 18075342
44. Behavior change intervention research in community settings: how generalizable are the results? Dzewaltowski DA, Estabrooks PA, Klesges LM, Bull S, Glasgow RE, Health Promot Int 2004 19 235 245 10.1093/heapro/dah211 15128715 (Pubitemid 38724515)
45. Cardiovascular disease prevention and lifestyle interventions: effectiveness and efficacy. Haskell WL, J Cardiovasc Nurs 2003 18 245 255 14518600
46. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ, BMJ 2001 322 1019 1023 10.1136/bmj.322.7293.1019 11325764